Syntaxin’s TSI are novel recombinant proteins designed to exploit the unique pharmacology inherent in bacterial toxins
View how it works >
Syntaxin focuses its programmes in therapeutic areas where there is a high unmet need.
View Patient Focus >
Syntaxin has an alliance with Allergan, Inc. a world leader in the commercialisation of botulinum neurotoxin products to discover, develop and commercialise TSI for the treatment of pain in humans.
08 May 2012
Syntaxin to Present at Bio€quity Europe 2012
Oxford (UK), 8 May 2012 – Syntaxin, a biotechnology company specialisi...
29 March 2012
Melanie Lee, CEO of Syntaxin, joins the Board of Lundbeck
Oxford (UK), 29 March 2012 - Syntaxin, a biotechnology company special...
BioEquity Europe 2012 15-16 May 2012. Frankfurt, Germany
The Biopharmaceutical Conference in Europe 13-15 June 2012. Cannes, France